Inovio Pharma (INO)
$11.38 0.03 (0.26%)
5:29 EDT INO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 1.04B
PE Ratio -9.98
Volume (Avg. Vol.) 638
Day's Range 11.35 - 11.35
52-Week Range 2.09 - 33.79
Dividend & Yield N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
- From InvestorPlace
- From the Web
INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.
By Joel Baglole
INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.
A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper.
INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?
By Ian Cooper
INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.
The market is sliding on today on Trump coronavirus news following confirmation that President Donald Trump tested positive.
Inovio has lost the race for a novel coronavirus vaccine. And INO stock could plummet, given increasing doubts about the company as a whole.
Inovio Pharmaceuticals fell 28% after the FDA put a partial clinical hold on vaccine trial. Should you buy INO stock on the dip?
Trends come and trends go, but INO stock is coming back but innovation never goes out of style. Hold on trials hurts, but doesn't kill yet.
Inovio Pharmaceuticals (INO) news for Monday includes the pausing of its vaccine trial for the novel coronavirus sending INO stock lower.
It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.
INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.
After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.
Inovio's DNA-based approach gives potential advantages to its Covid-19 vaccine candidate and adds fuel to the volatility of INO stock.
INO stock traders may be skeptical about Inovio's main Covid-19 vaccine candidate, but the CEO made a convincing case to stay in the trade.
Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.
Twilio, Micron, Ford, Inovio and U.S. Steel were our top stock trades for Friday. So, let's have a look at the charts to see what's new.
By Alex Sirois
Curious why INO stock jumped in recent trading? Overall optimism wasn't the only reason. Read on to gain some perspective on its chances.
Inovio Pharmaceuticals teased investors on Monday that Phase 1 results were just around the corner. INO stock is still rallying. Here's why.
From Market News Video
Navellier RatingsPowered by Portfolio Grader